125 related articles for article (PubMed ID: 35311086)
1. Investigating the Clinico-Molecular and Immunological Evolution of Lung Adenocarcinoma Using Pseudotime Analysis.
Lee H; Choi H
Front Oncol; 2022; 12():828505. PubMed ID: 35311086
[TBL] [Abstract][Full Text] [Related]
2. Single-cell profiling reveals the trajectory of FOLR2-expressing tumor-associated macrophages to regulatory T cells in the progression of lung adenocarcinoma.
Xiang C; Zhang M; Shang Z; Chen S; Zhao J; Ding B; Jiang D; Zhu Q; Teng H; Zhu L; Shao J; Zhao R; Ye M; Yu Y; Han Y
Cell Death Dis; 2023 Aug; 14(8):493. PubMed ID: 37532692
[TBL] [Abstract][Full Text] [Related]
3. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
4. NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.
Yan Y; Gao Z; Han H; Zhao Y; Zhang Y; Ma X; Chen H
J Cancer Res Clin Oncol; 2022 Mar; 148(3):565-575. PubMed ID: 34746975
[TBL] [Abstract][Full Text] [Related]
5. Association between immunotherapy biomarkers and glucose metabolism from F-18 FDG PET.
Kim BS; Kang J; Jun S; Kim H; Pak K; Kim GH; Heo HJ; Kim YH
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8288-8295. PubMed ID: 32894535
[TBL] [Abstract][Full Text] [Related]
6. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
Dong ZY; Zhang C; Li YF; Su J; Xie Z; Liu SY; Yan LX; Chen ZH; Yang XN; Lin JT; Tu HY; Yang JJ; Zhou Q; Sun YL; Zhong WZ; Wu YL
J Thorac Oncol; 2018 Jan; 13(1):85-96. PubMed ID: 29127022
[TBL] [Abstract][Full Text] [Related]
7. Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors.
Wen Y; Lin A; Zhu W; Wei T; Luo P; Guo L; Zhang J
Front Pharmacol; 2021; 12():645862. PubMed ID: 34163353
[No Abstract] [Full Text] [Related]
8. Discovery of tumor immune infiltration-related snoRNAs for predicting tumor immune microenvironment status and prognosis in lung adenocarcinoma.
Wan R; Bai L; Cai C; Ya W; Jiang J; Hu C; Chen Q; Zhao B; Li Y
Comput Struct Biotechnol J; 2021; 19():6386-6399. PubMed ID: 34938414
[TBL] [Abstract][Full Text] [Related]
9. Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma.
Gong Z; Jia Q; Chen J; Diao X; Gao J; Wang X; Zhu B
J Thorac Oncol; 2019 May; 14(5):857-866. PubMed ID: 30768970
[TBL] [Abstract][Full Text] [Related]
10. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
[TBL] [Abstract][Full Text] [Related]
13. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
14. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
[TBL] [Abstract][Full Text] [Related]
15. Association of
Jia M; Yao L; Yang Q; Chi T
Front Oncol; 2020; 10():168. PubMed ID: 32154170
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
18. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
[No Abstract] [Full Text] [Related]
19. Classification of lung adenocarcinoma based on stemness scores in bulk and single cell transcriptomes.
Liu Q; Lei J; Zhang X; Wang X
Comput Struct Biotechnol J; 2022; 20():1691-1701. PubMed ID: 35495113
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Wang D; Li Y; Chen X; Li P
Medicine (Baltimore); 2021 Sep; 100(35):e27100. PubMed ID: 34477147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
